Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
Pseudomonas aeruginosa remains an important cause of pulmonary disease in patients who have cystic fibrosis. The development of antimicrobial therapy directed against this organism has resulted in the preservation of lung function and improved longevity. Efficacy has been demonstrated with agents administered via parenteral, inhaled, and oral routes. The optimal antibiotic regimen remains unclear. There is an active effort to use randomized, controlled clinical trials to rigorously test effective antibiotic for the eradication of P aeruginosa in young children or at least to delay the establishment of chronic infection.
Lahiri
Thomas
T
University of Vermont College of Medicine, Burlington, VT 05401, USA. thomas.lahiri@vtmednet.org
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*
D000900:Anti-Bacterial Agents